AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3527555
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without medication
Trial: 23553534
Drug: Intravenous zanamivir
RxNorm normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous zanamivir 600 mg
Trial: 29566543
Drug: Beetroot-based gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot-based gel (BG) supplementation
Trial: 29566543
Drug: Nitrate-depleted gel
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-depleted gel (PLA)
Trial: 18676516
Drug: Video game
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Video game intervention addressing cancer treatment and care
Trial: 15995847
Drug: Sodium fusidate
RxNorm normalized name: Sodium fusidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium fusidate (fusidin; 500 mg orally three times daily for 4 weeks, then the same dose for two consecutive weeks a month followed by 2 weeks a month without the drug for 20 weeks)
Trial: 12795777
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of 500 mg clarithromycin tablet
Trial: 12795777
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of 500 mg clarithromycin tablet
Trial: 10332969
Drug: Self-administered joint
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered joint counts (JC)
Trial: 26728978
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g RUTF/day
Trial: 22111330
Drug: Candesartan and
RxNorm normalized name: candesartan and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan and amlodipine (combination therapy)
Trial: 15277162
Drug: Basic diet
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic diet (BD) with low calcium (224 mg Ca/d)
Trial: 15277162
Drug: BD with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BD with milk (826 mg Ca/d)
Trial: 15277162
Drug: BD with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BD with calcium lactate (802 mg Ca/d)
Trial: 15277162
Drug: BD with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BD with milk mineral isolate (801 mg Ca/d)
Trial: 11673021
Drug: Warfarin (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (2.5, 5 or 7.5 mg/day) plus levetiracetam 1000 mg bid
Trial: 11673021
Drug: Warfarin (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (2.5, 5 or 7.5 mg/day) plus placebo
Trial: 7932170
Drug: Ethacrynic acid
RxNorm normalized name: Ethacrynic Acid
DrugBank: Etacrynic acid (DB00903)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethacrynic acid (EA) 100 mg administered intravenously (i.v.)
Trial: 7932170
Drug: Ethacrynic acid
RxNorm normalized name: Ethacrynic Acid
DrugBank: Etacrynic acid (DB00903)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethacrynic acid (EA) 100 mg administered orally (p.o.)
Trial: 7932170
Drug: Ethacrynic acid
RxNorm normalized name: Ethacrynic Acid
DrugBank: Etacrynic acid (DB00903)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethacrynic acid (EA) administered by both routes
Trial: 7932170
Drug: Ethacrynic acid
RxNorm normalized name: Ethacrynic Acid
DrugBank: Etacrynic acid (DB00903)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethacrynic acid (EA) administered intravenously (i.v.)
Trial: 3501375
Drug: Continuous prophylaxis
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous prophylaxis with trimethoprim-sulfamethoxazole (5-25 mg/kg/day/p.o.)
Trial: 3501375
Drug: Intermittent prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent prophylaxis with trimethoprim-sulfamethoxazole (3 days/week, 5-25 mg/kg/day/p.o.)
Trial: 22877848
Drug: Temozolomide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temozolomide (200 mg/m² on days 1-5 of every 28 days for up to six cycles)
Trial: 22877848
Drug: Hypofractionated radiotherapy
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated radiotherapy (34.0 Gy administered in 3.4 Gy fractions over 2 weeks)
Trial: 22877848
Drug: Temozolomide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temozolomide (200 mg/m²)
Trial: 16091766
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral 800 IU (727 mg) of alpha‐tocopherol and 500 mg of vitamin C (n = 24)
Trial: 16091766
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (n = 24)
Trial: 12204662
Drug: Integration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integration of biological response assessment
Trial: 10519481
Drug: Betaxolol hydrochloride
RxNorm normalized name: Betaxolol Hydrochloride
DrugBank: Betaxolol (DB00195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betaxolol hydrochloride ophthalmic solution 0.5%
Trial: 7735340
Drug: Fat counseling
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat counseling (20 g/day fat reduction)
Trial: 2404555
Drug: Radiotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy and combination chemotherapy (cyclophosphamide, Adriamycin, methotrexate, procarbazine)
Trial: 7369096
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose heparin (500 units by intravenous infusion every 12 hours)
Trial: 7369096
Drug: Fully anticoagulated
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fully anticoagulated group (heparin by intravenous infusion and warfarin sodium to maintain a whole blood clotting time of 30 to 90 minutes and a prothrombin index of 10% to 35%)
Trial: 31202468
Drug: Deferiprone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferiprone (30 mg/kg per day divided into two equal doses)
Trial: 20963404
Drug: Tipranavir/ritonavir (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tipranavir/ritonavir (500 mg with 200 mg ritonavir, steady state)
Trial: 20963404
Drug: Valacyclovir (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir (single dose)
Trial: 15808927
Drug: Standardized test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized test with 250 ml fluid meal (250 kcal: 9.4 g protein, 34.4 g carbohydrates, and 8.3 g fat) at admission
Trial: 15808927
Drug: Standardized test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized test with 250 ml fluid meal after partial weight gain (2.8 +/- 0.1 kg; BMI 16.1 +/- 0.3 kg/m2)
Trial: 15808927
Drug: Standardized test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized test with 250 ml fluid meal at discharge (weight gain: 7.6 +/- 0.5 kg; BMI 17.9 +/- 0.4 kg/m2)
Trial: 1960553
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interleukin‐3 (rhIL‐3) administered by a single intravenous (IV) bolus injection followed by subcutaneous (SC) injections once daily from day 2 to 15 at doses of 60, 125, 250, and 500 micrograms/m2
Trial: 31426321
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (400 mg/day for 3 weeks)
Trial: 28480762
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg tenofovir disoproxil fumarate, 300 mg lamivudine, 400/100 mg lopinavir/ritonavir
Trial: 28480762
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg tenofovir disoproxil fumarate, 300 mg lamivudine, 400 mg nevirapine
Trial: 19287011
Drug: Ganciclovir (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir (6 mg/kg iv every 12 h for 6 weeks)
Trial: 15684260
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (0.2% ropivacaine and 0.003% morphine)
Trial: 15684260
Drug: Morphine group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine group (0.003% morphine)
Trial: 10743823
Drug: Tramadol (200-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (200-400 mg/day)
Trial: 8708983
Drug: Orally dissolving
RxNorm normalized name: MUCOTROL Sugar-free Orally Dissolving Wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally dissolving tablet (ODT) containing 99mTc‐labelled cholestyramine resin
Trial: 8708983
Drug: 1.5 mL
RxNorm normalized name: Humulin 70/30 1.5 ML Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mL aqueous suspension of 99mTc‐labelled cholestyramine resin
Trial: 8708983
Drug: Both dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dosage forms (ODT and aqueous suspension)
Trial: 1960302
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with recombinant tissue‐type plasminogen activator or urokinase
Trial: 7139504
Drug: Inhaled powder
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled powder (200 micrograms)
Trial: 7139504
Drug: Inhaled powder
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled powder (400 micrograms)
Trial: 20679260
Drug: Systematic Treatment
RxNorm normalized name: Integrase Inhibitors, antiinfectives for systematic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic Treatment Selection (STS) for Psychodynamic Therapy (PDT)
Trial: 20679260
Drug: Random Treatment
RxNorm normalized name: Nerandomilast
DrugBank: Nerandomilast (DB18237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random Treatment Selection (RTS) for Psychodynamic Therapy (PDT)
Trial: 20679260
Drug: Systematic Treatment
RxNorm normalized name: Integrase Inhibitors, antiinfectives for systematic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic Treatment Selection (STS) for Cognitive-Behavioural Therapy (CBT)
Trial: 20679260
Drug: Random Treatment
RxNorm normalized name: Nerandomilast
DrugBank: Nerandomilast (DB18237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random Treatment Selection (RTS) for Cognitive-Behavioural Therapy (CBT)
Trial: 16368054
Drug: RSG 4
RxNorm normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RSG 4 mg/day (increased to 8 mg/day) + MET 1000 mg/day (total 1500 mg/day)
Trial: 16368054
Drug: MET 500
RxNorm normalized name: cefetamet 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MET 500 mg/day (increased to 2000 mg/day)
Trial: 8521882
Drug: Carvedilol 25
RxNorm normalized name: carvedilol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 25 mg b.i.d for 2 weeks followed by 50 mg b.i.d for a further 2 weeks
Trial: 8521882
Drug: Intravenous carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous carvedilol followed by oral carvedilol 50 mg b.i.d for 8 weeks
Trial: 2677532
Drug: Aspirin, 80
RxNorm normalized name: Non-Aspirin, 80 mg/0.8 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 80 mg/day
Trial: 29934249
Drug: 2 mA
RxNorm normalized name: Alpha 2 macroglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mA tDCS administered for 10 sessions of 20 minutes each on five consecutive days (two sessions per day)
Trial: 29934249
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered for 10 sessions of 20 minutes each on five consecutive days (two sessions per day)
Trial: 22430640
Drug: Streaming weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streaming weekly soap opera video episodes to smartphones
Trial: 22430640
Drug: Weekly HIV
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly HIV risk reduction written messages to smartphones
Trial: 18304620
Drug: Yttrium‐90‐labeled human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yttrium‐90‐labeled human milk fat globule 1 murine monoclonal antibody (90Y‐muHMFG1)
Trial: 15830972
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment with medical and physical therapy
Trial: 10484900
Drug: H2 receptor
RxNorm normalized name: Histamine H2 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2 receptor antagonists (Group A)
Trial: 9085534
Drug: Adjustable oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjustable oral appliances (OA)
Trial: 7128187
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g glucosamine sulphate daily
Trial: 7128187
Drug: 1.2 g
RxNorm normalized name: Humidifier 1.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g ibuprofen daily
Trial: 22425689
Drug: Microencapsulated Lactobacillus
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microencapsulated Lactobacillus reuteri NCIMB 30242 in yogurt, 5 × 10(10) CFU, twice/day for 6 weeks
Trial: 15807452
Drug: Colloid bismuth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloid bismuth subcitrate (CBS) 240 mg twice a day + amoxicillin 2 g/day and furozolidon 400 mg/day (subgroup 1a, n = 10)
Trial: 15807452
Drug: Colloid bismuth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloid bismuth subcitrate (CBS) monotherapy 240 mg twice a day (subgroup 1b, n = 20)
Trial: 15807452
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg twice a day (group 2, n = 15)
Trial: 9505333
Drug: Ultrasonic debridement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonic debridement with 24% EDTA solution as irrigation agent
Trial: 8475962
Drug: Acetaminophen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (10 micrograms/ml)
Trial: 8475962
Drug: Acetaminophen (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (100 micrograms/ml)
Trial: 8475962
Drug: Indomethacin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (10 micrograms/ml)
Trial: 3092657
Drug: Enprostil 70
RxNorm normalized name: enprostil
DrugBank: Enprostil (DB13824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprostil 70 micrograms twice daily
Trial: 3092657
Drug: Enprostil 70
RxNorm normalized name: enprostil
DrugBank: Enprostil (DB13824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprostil 70 micrograms twice daily (in smokers)
Trial: 3092657
Drug: Enprostil 35
RxNorm normalized name: enprostil
DrugBank: Enprostil (DB13824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprostil 35 micrograms twice daily (in smokers)
Trial: 26233499
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg intraarticular triamcinolone acetonide
Trial: 26233499
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg intraarticular triamcinolone acetonide
Trial: 24264552
Drug: Pregabaline 150
RxNorm normalized name: pregabalin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabaline 150 mg 1 hr before operation and 75 mg 12 hr after operation
Trial: 24264552
Drug: Placebo empty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo empty capsule
Trial: 18942248
Drug: Pethidine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine 1.5 mg/kg (Group P)
Trial: 16798309
Drug: BioGlue (surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BioGlue (surgical treatment and BioGlue)
Trial: 16798309
Drug: Control (surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (surgical treatment only)
Trial: 26579629
Drug: Computer-assisted cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-assisted cognitive behavioral therapy for anxiety
Trial: 22827782
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose zinc supplementation (50 mg elemental Zn sulfate daily)
Trial: 22827782
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose zinc supplementation
Trial: 17300591
Drug: DPP-IV inhibitors
RxNorm normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPP-IV inhibitors (e.g., vildagliptin, sitagliptin)
Trial: 16392769
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid supplements (1,800 mg/day)
Trial: 16392769
Drug: Diet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet therapy (control group)
Trial: 11979054
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg cortisol intravenously
Trial: 29548729
Drug: Hyperbaric-Oxygen Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric-Oxygen Therapy (HBOT) at 2.0 ATA for 60 sessions
Trial: 29548729
Drug: Hyperbaric-Oxygen Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric-Oxygen Therapy (HBOT) at 2.0 ATA for 90 sessions
Trial: 29548729
Drug: Hyperbaric-Oxygen Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric-Oxygen Therapy (HBOT) at 1.5 ATA for 60 sessions
Trial: 29548729
Drug: Hyperbaric-Oxygen Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric-Oxygen Therapy (HBOT) at 1.5 ATA for 90 sessions
Trial: 17325899
Drug: Pixantrone 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pixantrone 80 mg/m2, methylprednisolone 500 mg, cisplatin 25 mg/m2, cytarabine 2000 mg/m2
Trial: 15049795
Drug: Sirolimus (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (1, 3, 9, or 15 mg/m(2))
Trial: 11875681
Drug: 0.25% nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% nitroglycerin topically (administered in two daily applications for two weeks)
Trial: 11875681
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (placebo)
Trial: 28629540
Drug: Intranasal Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal Oxytocin (OXT) at a dose of 24 international units, administered 45-70 minutes prior to testing
Trial: 25281353
Drug: Mendelian randomisation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mendelian randomisation analysis using SNPs related to 25(OH)D synthesis and metabolism.
Trial: 21084392
Drug: Intraarterial ghrelin
RxNorm normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial ghrelin infusion (4.2 ng × kg(‐1) × min(‐1))
Trial: 21084392
Drug: Intraarterial placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial placebo infusion
Trial: 19335977
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil in combination with lamivudine for the first 12 weeks and adefovir dipivoxil only for the following 36 weeks
Trial: 19335977
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil in combination with lamivudine for 48 weeks
Trial: 17602082
Drug: Single high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single high-dose chemotherapy (CE): one cycle of cisplatin 100 mg/m2, etoposide 375 mg/m2, and ifosfamide 6 g/m2 plus three cycles of high-dose carboplatin 1,500 mg/m2 and etoposide 1,500 mg/m2
Trial: 17602082
Drug: Sequential high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential high-dose chemotherapy (CEC): three cycles of VIP plus one cycle of high-dose carboplatin 2,200 mg/m2, etoposide 1,800 mg/m2, and cyclophosphamide 6,400 mg/m2
Trial: 15910203
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 0.25 mg/kg body weight
Trial: 15910203
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 0.5 mg/kg body weight
Trial: 12111764
Drug: Acetaminophen 650
RxNorm normalized name: acetaminophen 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 650 mg PO and diphenhydramine 25 mg IV
Trial: 2037709
Drug: Rifampin 600
RxNorm normalized name: rifampin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 600 mg/d
Trial: 31163689
Drug: Herbal mixture
RxNorm normalized name: Elm 65 mg in 5 mL ORAL SYRUP [AFRICAN SEA-COCONUT Herbal Mixture]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal mixture (700 mg daily)
Trial: 31163689
Drug: Herbal mixture
RxNorm normalized name: Elm 65 mg in 5 mL ORAL SYRUP [AFRICAN SEA-COCONUT Herbal Mixture]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal mixture (700 mg daily) along with Clomiphene Citrate (CC) (50-150 mg for 3 months)